Singapore Institute of Advanced Medicine Holdings

SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

RENOUNCEABLE NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE

- CLARIFICATION ON SHAREHOLDERS' APPROVAL

Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings as in the Announcements (as defined below).

The Board of Directors (the "**Board**") of Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**", together with its subsidiaries, collectively, the "**Group**") refers to the Company's announcements dated 30 October 2025, 13 February 2026, 22 April 2026 and 12 May 2026 (collectively, the "**Announcements**") in relation to, *inter alia*, the renounceable non-underwritten rights cum warrants issue of up to 492,597,856 new ordinary shares in the capital of the Company ("**Rights Shares**") at an issue price of S$0.031 for each Rights Share, with up to 492,597,856 free detachable warrants ("**Warrants**"), each Warrant carrying the right to subscribe for one (1) new Share ("**Warrant Share**") at an exercise price of S$0.050 for each Warrant Share, on the basis of two (2) Rights Shares with two (2) free Warrants for every five (5) existing Shares held by the Shareholders as at a date and time to be determined by the Directors for the purpose of determining Shareholders' entitlements, fractional entitlements to be disregarded (the "**Rights cum Warrants Issue**").

As set out in the Company's update announcement dated 22 April 2026, the Rights cum Warrants Issue will be undertaken pursuant to the General Share Issuance Mandate approved by Shareholders at the annual general meeting of the Company held on 28 October 2025. Accordingly, specific Shareholders' approval is not required in respect of the Rights cum Warrants Issue, as the Rights Shares with Warrants will be issued pursuant to, and within the limits of, the General Share Issuance Mandate.

The Board wishes to clarify that, due to system limitations of the SGXNET announcement template for such rights issue exercises, the field under the sub-header "Shareholders' Approval Required?", which had been populated in announcements released prior to 22 April 2026, could not be updated to reflect the above position, and should accordingly reflect "No".

To facilitate the continued use of the prescribed "Rights Issue" template on SGXNET for subsequent announcements relating to the Rights cum Warrants Issue, the announcement template has indicated that Shareholders' approval has been obtained in respect of the Rights cum Warrants Issue. This clarification is therefore provided to ensure that the disclosure remains consistent across all announcements relating to the Rights cum Warrants issue.

Save as disclosed above and in the Announcements, all other information in relation to the Rights cum Warrants Issue remains unchanged.

Further announcements will be made by the Company in relation to the Rights cum Warrants Issue as and when appropriate.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
20 May 2026

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.